STOCK TITAN

Blueberries Medi - BBRRF STOCK NEWS

Welcome to our dedicated page for Blueberries Medi news (Ticker: BBRRF), a resource for investors and traders seeking the latest updates and insights on Blueberries Medi stock.

Blueberries Medical Co (BBRRF) is a leading medical cannabis company focused on the production and distribution of pharmaceutical-grade cannabis products. With a strong presence in Latin America, the company is known for its innovative research, state-of-the-art facilities, and commitment to patient care. Blueberries Medical Co is dedicated to improving the quality of life for individuals through the therapeutic benefits of medical cannabis.

Rhea-AI Summary

Blueberries Medical Corp (CSE: BBM) (OTC: BBRRF) has announced a non-brokered private placement of 96,064,935 common shares at C$0.011 per share, aiming to raise approximately C$1.05 million (US$740,000). The offering is expected to close on March 25, 2025.

The placement will be led by Terraflos Inc, a Latin American company controlled by Facundo Garreton, who serves as Blueberries' Chairman, CEO, and director. The proceeds will be used to fund and expand operations, and for general corporate and working capital purposes.

Following the offering, Garreton's ownership through Terraflos will increase to approximately 62.67% of outstanding Common Shares on a partially diluted basis, up from 61.23% prior to the offering. The transaction qualifies as a related party transaction but is exempt from formal valuation and minority shareholder approval requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-11.11%
Tags
private placement
-
Rhea-AI Summary

Blueberries Medical Corp (CSE: BBM) (OTC: BBRRF) has announced a non-brokered private placement of 96,064,935 common shares at C$0.011 per share, aiming to raise approximately C$1.05 million (US$740,000). The offering is expected to close around March 25, 2024.

The placement will be primarily led by Terraflos Inc, a Latin American cannabis company controlled by Facundo Garreton, who serves as Blueberries' Chairman, CEO, and director. Director Guillermo Rodriguez is also expected to participate in the offering.

The net proceeds will be utilized to fund and expand operations, along with general corporate and working capital purposes. The transaction qualifies as a 'related party transaction' under MI 61-101, with exemptions from formal valuation and minority shareholder approval requirements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
56.25%
Tags
private placement
-
Rhea-AI Summary
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) announces a non-brokered private placement of 180,716,00 common shares at a price of C$0.011 per share, resulting in gross proceeds of approximately C$1,987,876. The net proceeds will be used to repay existing debt and for general corporate and working capital purposes. The Offering was led by Terraflos Inc., a company with operations throughout Latin America, aiming to expand its operations into Argentina, Mexico, and Brazil. Facundo Garreton, the Chairman, CEO, and a director of Blueberries, and Terraflos, acquired the common shares for investment purposes, increasing their beneficial ownership to approximately 61.93% of the outstanding common shares on a partially diluted basis.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.14%
Tags
none
Rhea-AI Summary
Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) (FRA: 1OA) announces a non-brokered private placement of 180,716,000 common shares at C$0.011 per share, generating approximately C$1,987,876 in gross proceeds. The net proceeds will be used to repay existing debt and for general corporate and working capital purposes.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
41.25%
Tags
none
-
News
Rhea-AI Summary
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.42%
Tags
none
-
Rhea-AI Summary

Blueberries Medical Corp. (OTC: BBRRF) reported financial results for the year ending December 31, 2022. The company generated revenues of $235,449, a significant increase of 70% over 2021 due to new product introductions like CBD isolate. Total current assets rose to $2,185,642 from $1,563,617, while total liabilities decreased to $1,886,394 from $2,159,134. The net loss narrowed to $1,467,876 from $5,147,012, driven by increased sales and cost reductions in various operational areas. Blueberries aims to achieve break-even sales levels and expand market reach with operations in Argentina and a new shipment to Australia. The CEO expressed cautious optimism as the company awaits regulatory changes in Colombia.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.41%
Tags
Rhea-AI Summary

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) has successfully completed a non-brokered private placement, issuing 54,498,889 common shares at CAD$0.027 each, raising approximately CAD$1.47 million (US$1.1 million). The funds will enhance production capabilities, upgrade infrastructure, and expand business networks into Europe, the USA, and Australia. The company pivoted to extraction services, generating CAD$178,397 in revenue for the first nine months of 2022, while reducing operational costs. However, the company reported a net loss of CAD$1.47 million in the same period.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.91%
Tags
-
Rhea-AI Summary

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) reports significant growth in Q2 2022, doubling revenues to $39,826, driven by extraction services. The shift towards extraction services and successful exports to Argentina support their strategic pivot. The company has established a partnership for GACP CUMSC certified CBD and THC strains and is exploring new markets with innovative water-soluble products. However, operational costs surged, leading to a net loss of $511,717, raising concerns about expense management despite revenue growth.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
-
Rhea-AI Summary

Blueberries Medical Corp. (CSE: BBM, OTC: BBRRF) announced significant strides in its operations, including over 60 kg of CBD and non-psychoactive product shipments to Argentina. The company expects annual sales exceeding $2.5 million for 2023. Additionally, Blueberries received Colombian licenses for psychoactive cannabis exports and partnered with YVY Life Sciences to enhance operations. Operational expenses have decreased significantly, with plans to complete a GMP-compliant extraction lab by Q1 2023. A debt extension worth C$1 million is also disclosed, with a related party transaction highlighted.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
16.3%
Tags
partnership
Rhea-AI Summary

Blueberries Medical Corp. (CSE: BBM) (OTC: BBRRF) released its Q1 2022 financial results, reporting revenues of $33,715, a significant increase compared to $23,120 in Q1 2021. Despite a gross profit of $13,918, the company incurred a net loss of $656,307, up from $590,325 a year earlier, primarily due to increased operational costs. The company is moving towards expanding revenues through new extraction services and partnerships in Latin America, while focusing on minimizing expenses and optimizing cash flow.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
9.72%
Tags

FAQ

What is the current stock price of Blueberries Medi (BBRRF)?

The current stock price of Blueberries Medi (BBRRF) is $0.0108 as of April 1, 2025.

What is the market cap of Blueberries Medi (BBRRF)?

The market cap of Blueberries Medi (BBRRF) is approximately 3.3M.

What does Blueberries Medical Co specialize in?

Blueberries Medical Co specializes in the production and distribution of pharmaceutical-grade medical cannabis products.

Where does Blueberries Medical Co operate?

Blueberries Medical Co has a strong presence in Latin America, with a focus on research, innovation, and patient care.

What sets Blueberries Medical Co apart from other cannabis companies?

Blueberries Medical Co stands out for its commitment to pharmaceutical-grade products, advanced facilities, and dedication to improving patient quality of life.

Does Blueberries Medical Co engage in research and development?

Yes, Blueberries Medical Co is actively involved in innovative research to enhance the therapeutic benefits of medical cannabis.

How does Blueberries Medical Co contribute to the medical cannabis industry?

Blueberries Medical Co contributes to the industry by setting high standards for quality, safety, and patient care in the production of medical cannabis products.

What is the mission of Blueberries Medical Co?

The mission of Blueberries Medical Co is to improve the quality of life for individuals through the therapeutic benefits of medical cannabis.

Does Blueberries Medical Co have any notable partnerships?

Blueberries Medical Co collaborates with industry leaders to drive innovation, expand market reach, and enhance patient care.

What are some of the core values of Blueberries Medical Co?

Some core values of Blueberries Medical Co include integrity, quality, innovation, and compassion for patients.

How does Blueberries Medical Co ensure product quality and safety?

Blueberries Medical Co maintains strict standards for product quality and safety through rigorous testing, compliance with regulations, and continuous improvement initiatives.

What are the future plans and goals of Blueberries Medical Co?

Blueberries Medical Co aims to expand its market presence, introduce new product lines, and continue advancing research efforts to offer cutting-edge medical cannabis solutions.
Blueberries Medi

OTC:BBRRF

BBRRF Rankings

BBRRF Stock Data

3.33M
56.02M
61.89%
Drug Manufacturers - Specialty & Generic
Healthcare
Link
Canada
Vancouver